Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Targin oxycodone/naloxone: Phase III data

Mundipharma said Targin met the primary endpoint of reduction in the symptoms of constipation compared to oxycodone PR alone in a subset

Read the full 227 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE